Fate Therapeutics, Inc. (FATE)
Engineers immune cells to fight cancer and autoimmune diseases.
$2.33-0.04%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+117.3%
The outlook
FATE is trading near the middle of its 52-week range after a flat day. Analyst coverage leans bullish, with an average price target about 133% above the current price, suggesting meaningful upside in their view. The stock sits mixed against its moving averages, reflecting some near-term uncertainty despite the broader optimistic analyst sentiment.
What’s behind the score
Price trendMixed vs its moving averages
52-week range61% of the way from its 52-week low to high
Price targetAvg target +133% vs current price
Analyst price target
~12-month · 9 analysts$5.41average target+132.7% vs now
Now $2.33
Low $2.20High $8.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$271.0M
52-wk high
$3.23
52-wk low
$0.91
50-day avg
$2.39
200-day avg
$1.55
Trailing P/E
—